Taylor Wirth was quoted in a MedCity News article, "A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets," regarding the difference between an IPO and a direct listing and why a biotech company might choose one over the other.
Media Mentions
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets
September 8, 2024
Nashville
RELATED PEOPLE
×
Subscribe
Do you want to receive more valuable insights directly in your inbox? Visit our subscription center and let us know what you're interested in learning more about.
View Subscription Center
/Passle/6488d4630e7e25c9ac9f834a/SearchServiceImages/2024-11-14-13-11-27-495-6735f6fff42d6cc59c8ec5c1.jpg)
/Passle/6488d4630e7e25c9ac9f834a/SearchServiceImages/2024-11-11-22-02-38-042-67327efe31216b909e6ea644.jpg)
